血清FGF21和SIRT3水平对慢性心力衰竭患者病情及预后评估的价值OACSTPCD
Value of serum FGF21 and SIRT3 levels in assessing the condition and prognosis of patients with chronic heart failure
目的:对慢性心力衰竭(congestive heartfailure,CHF)患者的病情及预后进行早期评估有助于降低其病死率,改善其预后.本研究旨在探索CHF患者血清成纤维细胞生长因子21(fibroblast growth factor 21,FGF21)和沉默信息调节因子2相关酶3(silent information regulator factor 2 related enzyme 3,SIRT3)水平及其在患者病情及预后评估中的应用价值…查看全部>>
Objective:Early assessment of the condition and prognosis of patients with chronic heart failure(CHF)helps reduce mortality and improve prognosis.This study aims to explore the levels of serum fibroblast growth factor 21(FGF21)and silent information regulator factor 2 related enzyme 3(SIRT3)in CHF patients and their value in assessing the patients'condition and prognosis. Methods:A total of 164 patients diagnosed with CHF from January 2021 to June 2022 were …查看全部>>
饶培玲;郑裴裴
郑州大学第一附属医院心血管内科三病区,郑州 450000郑州大学第一附属医院心血管内科三病区,郑州 450000
慢性心力衰竭成纤维细胞生长因子21沉默信息调节因子2相关酶3预后应用价值
chronic heart failurefibroblast growth factor 21silent information regulator 2 related enzyme 3prognosisapplication value
《临床与病理杂志》 2024 (5)
681-688,8
河南省卫生健康委员会资助项目(LHGJ20220934).This work was supported by the Henan Provincial Health Commission Project,China(LHGJ20220934).
评论